Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 45 h ago

Cabaletta Bio, Inc.: Cormorant Asset Management, LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Cormorant Asset Management amended its Schedule 13G filing on Cabaletta Bio, disclosing a revised passive stake in the clinical-stage cell therapy developer. The filing, submitted under SEC accession 0001172661-26-005291, updates Cormorant's previously reported beneficial ownership position in the company. Schedule 13G amendments are typically triggered when an institutional holder's stake crosses or adjusts past the 5% reporting threshold, though the filing summary did not specify the exact percentage change. The update matters because it signals a shift in a major institutional investor's exposure to Cabaletta, whose share price is sensitive to ownership changes among specialist biotech funds. Investors will watch for the full filing details to confirm whether Cormorant increased or trimmed its position, and for any subsequent 13F or Form 4 disclosures that clarify the direction of the trade.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Cabaletta Bio, Inc., Cormorant Asset Management, LP